About this study
Background
The Healthy City Study aims to establish an integrated disease serosurveillance platform in Sierra Leone using dried blood spots. Randomly selected members of HEAL-SL households are offered a health check and a finger-prick blood sample, to be tested for antibodies to priority pathogens.
Design
The plan was for 10,000 to 12,000 samples from 46 enumeration areas in Bo District, a second phase in Freetown, a Luminex MagPix platform at Njala University and a T-cell sub-study of 30 adults.
What was done
In total 7,854 samples were collected and stored at the Mercy Hospital Laboratory in Bo: about 4,200 adults in urban Bo (June to August 2021; the published SARS-CoV-2 analysis reports 4,160), 2,654 adults in rural Bo (May to July 2022) and 1,000 children (September 2022). The MagPix platform was installed at the Mercy Hospital Laboratory. A preliminary analysis of about 2,000 samples was presented at the national mortality symposium in Freetown in December 2023. No Freetown phase or T-cell sub-study has been reported.
Status
SARS-CoV-2 results from the 2021 round are published (see "High SARS-CoV-2 seroincidence but low excess COVID mortality in Sierra Leone in 2020-2022"). Analysis of the multiplex antibody data continues. A manuscript was being drafted in November 2026, and no multiplex results are published yet.
Study team
- Partners
- Njala University
- Ministry of Health
- Centre for Global Health Research, University of Toronto
- Mercy Hospital Laboratory, Bo
- Bill & Melinda Gates Foundation (funder)
- Study leads
- Prof Rashid Ansumana — Njala University
- Prof Prabhat Jha — University of Oxford